Bokf Na grew its stake in shares of Pfizer Inc. (NYSE: PFE – Get Rating) by 4.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 525,023 shares of the biopharmaceutical company stock after purchasing an additional 20,284 shares during the quarter. Bokf Na’s holdings in Pfizer were worth $ 31,003,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in PFE. OLD Mission Capital LLC acquired a new stake in Pfizer during the third quarter worth approximately $ 291,000. Morgan Stanley increased its holdings in shares of Pfizer by 3.4% in the 2nd quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company stock valued at $ 1,875,532,000 after acquiring an additional 1,582,052 shares during the period. Center for Financial Planning Inc. increased its holdings in shares of Pfizer by 1.9% in the 3rd quarter. Center for Financial Planning Inc. now owns 17,073 shares of the biopharmaceutical company stock valued at $ 734,000 after acquiring an additional 313 shares during the period. New World Advisors LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at $ 292,000. Finally, EagleClaw Capital Managment LLC increased its holdings in shares of Pfizer by 2.1% in the 3rd quarter. EagleClaw Capital Managment LLC now owns 29,959 shares of the biopharmaceutical company stock valued at $ 1,287,000 after acquiring an additional 625 shares during the period. 66.50% of the stock is currently owned by institutional investors.
PFE has been the topic of a number of recent research reports. Citigroup lifted their target price on shares of Pfizer from $ 46.00 to $ 57.00 and gave the company a “neutral” rating in a report on Tuesday, April 5th. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. JPMorgan Chase & Co. set a $ 57.00 price objective on shares of Pfizer in a research note on Tuesday, May 3rd. Wells Fargo & Company dropped their price objective on shares of Pfizer from $ 60.00 to $ 55.00 in a research note on Wednesday, May 4th. Finally, Berenberg Bank set a $ 50.00 price objective on shares of Pfizer in a research note on Friday, May 27th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $ 57.26.
PFE opened at $ 46.53 on Friday. The firm has a 50 day moving average price of $ 50.90 and a 200 day moving average price of $ 52.34. The company has a market cap of $ 261.08 billion, a PE ratio of 10.67, a price-to-earnings-growth ratio of 0.58 and a beta of 0.76. Pfizer Inc. has a 1 year low of $ 38.70 and a 1 year high of $ 61.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.
Pfizer (NYSE: PFE – Get Rating) last posted its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $ 1.66 by ($ 0.04). The business had revenue of $ 25.66 billion for the quarter, compared to analyst estimates of $ 24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm’s revenue for the quarter was up 76.8% compared to the same quarter last year. During the same period last year, the company posted $ 0.93 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 6.61 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were issued a $ 0.40 dividend. This represents a $ 1.60 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date was Thursday, May 12th. Pfizer’s dividend payout ratio is presently 36.70%.
In other news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $ 53.96, for a total transaction of $ 227,603.28. Following the completion of the transaction, the senior vice president now directly owns 10,846 shares in the company, valued at approximately $ 585,250.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $ 50.50, for a total value of $ 202,000.00. Following the transaction, the senior vice president now owns 15,064 shares of the company stock, valued at $ 760,732. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,126 shares of company stock valued at $ 2,075,003. 0.05% of the stock is owned by company insiders.
Pfizer Company Profile: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.